Reaction of pyrido[2,1-a]isoindole with 1,4-naphtoquinone and study of the product by spectroscopic methods

Key role of the electronic structure of condensed isoindols in the way of the rearrangement was shown. Influence of the dienophile manifests in the requirement of the cyclic form of the dienophile itself. In the reaction of pyrido[2,1-a]isoindole with naphtoquinone rearrangement product of the first type was obtained and its structure was proven by spectral methods. Spectral criteria for the rearranged adducts of the first type for the pyrido[2,1-a]isoindole in the 13C NMR spectra were established. Products of reactions with naphthoquinone, 4-fluoro-, 2,5-difluorophenylmaleimides were isolated and characterized: (2E)-2-[(1,4-dihydroxy-2-naphthyl)(2-pyridin-2-ylphenyl)methylene]-4-hydroxynaphthalen-1(2H)-one, (3E)-1-(4-fluorophenyl)-3-[[1-(4-fluorophenyl)-2,5-dioxopyrrolidin-3-yl](2-pyridin-2-ylphenyl)methylene]pyrrolidine-2,5-dione, (3E)-1-(2,4-difluorophenyl)-3-[[1-(2,4-fluorophenyl)-2,5-dioxopyrrolidin-3-yl](2-pyridin-2-ylphenyl)methylene]pyrrolidine-2,5-dione

In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea

1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (TPPU) is a potent soluble epoxide hydrolase (sEH) inhibitor that is used extensively in research for modulating inflammation and protecting against hypertension, neuropathic pain, and neurodegeneration. Despite its wide use in various animal disease models, the metabolism of TPPU has not been well-studied. A broader understanding of its metabolism is critical for determining contributions of metabolites to the overall safety and effectiveness of TPPU. Herein, we describe the identification of TPPU metabolites using LC-MS/MS strategies. Four metabolites of TPPU (M1–M4) were identified from rat urine by a sensitive and specific LC-MS/MS method with double precursor ion scans. Their structures were further supported by LC-MS/MS comparison with synthesized standards. Metabolites M1 and M2 were formed from hydroxylation on a propionyl group of TPPU; M3 was formed by amide hydrolysis of the 1-propionylpiperdinyl group on TPPU; and M4 was formed by further oxidation of the hydroxylated metabolite M2. Interestingly, the predicted α-keto amide metabolite and 4-(trifluoromethoxy)aniline (metabolite from urea cleavage) were not detected by the LC-MRM-MS method. This indicates that if formed, the two potential metabolites represent <0.01% of TPPU metabolism. Species differences in the formation of these four identified metabolites was assessed using liver S9 fractions from dog, monkey, rat, mouse, and human. M1, M2, and M3 were generated in liver S9 fractions from all species, and higher amounts of M3 were generated in monkey S9 fractions compared to other species. In addition, rat and human S9 metabolism showed the highest species similarity based on the quantities of each metabolite. The presence of all four metabolites were confirmed in vivo in rats over 72-h post single oral dose of TPPU. Urine and feces were major routes for TPPU excretion. M1, M4 and parent drug were detected as major substances, and M2 and M3 were minor substances. In blood, M1 accounted for ~9.6% of the total TPPU-related exposure, while metabolites M2, M3, and M4 accounted for <0.4%. All four metabolites were potent inhibitors of human sEH but were less potent than the parent TPPU. In conclusion, TPPU is metabolized via oxidation and amide hydrolysis without apparent breakdown of the urea. The aniline metabolites were not observed either in vitro or in vivo. Our findings increase the confidence in the ability to translate preclinical PK of TPPU in rats to humans and facilitates the potential clinical development of TPPU and other sEH inhibitors

Étude de la synthèse des plakortolides : synthèses asymétriques de la ent-plakortolide I et de la seco-plakortolide E

In this thesis manuscript are described our synthetic efforts and the first total synthesis of two natural products isolated from the sponges of the genus Plakortis. In total, two different synthetic approaches were studied to finally accomplish the synthesis of plakortolide I. The first approach is an extension of the method developed by our group which consists in the creation of the 1,2-dioxane cycle by intramolecular opening of vinyl epoxide with β-hydroperoxy group. Firstly, we was interested in the preparation of alkoxymethylhexa-2,5-dien-1-ol. We have also tried to create the 1,2-dioxane cycle by double opening of bis-1,5-epoxide with hydrogen peroxide. Further more we have synthesised trisubstituted β-hydroperoxy vinyl epoxide, precursor of 1,2-dioxan ring, from R-epichlorohydrin. During this synthesis a procedure of chemoselective methylenation of ketone in the presence of epoxide by Nysted reagent and Ti(OiPr)2Cl2 was developed. Finally, (-)-ent-plakortolide I and seco-plakortolide E were synthesised by intramolecular Michael addition of hydroperoxide to double bond of the butenolide moietyDans ce mémoire de thèse sont décrits nos efforts synthétiques qui ont conduits à la première synthèse totale de deux produits naturels isolés d’éponges marines du genre Plakortis. Deux approches synthétiques des plakortolides ont été successivement étudiées pour finalement aboutir à la synthèse de la plakortolide I qui comporte un cycle endoperoxide à 6 chainons (1,2-dioxane). La première approche qui est une extension d’une méthode développée au laboratoire consistait à créer le cycle 1,2-dioxane par une ouverture intramoléculaire d’un époxyde vinylique par un groupement hydroperoxyde en β de l’époxyde. Dans un premier temps, nous nous sommes intéressés à la préparation d’un intermédiaire de synthèse, un alkoxyméthylhexa-2,5-dien-1-ol. Nous avons aussi tenté de créer le cycle 1,2-dioxane par une double ouverture d’un di époxyde 1,5 par de l’eau oxygénée. Nous avons ensuite modifié notre stratégie de synthèse en introduisant au début de la synthèse la chaine latérale de la plakortolide I en partant de la R-épichlorhydrine commerciale. Nous avons ainsi synthétisé le β-hydroperoxy vinyl époxyde trisubstitué, précurseur du cycle 1,2-dioxane. Lors de cette synthèse, nous avons mis au point une méthode efficace et chimiosélective de méthylenation d’une cétone en présence d’un ester utilisant le réactif de Nysted catalysé par Ti(OiPr)2Cl2. La seconde approche du système bicyclique peroxylactone fait appel à une addition de Michael intramoléculaire d’un hydroperoxyde sur la double liaison d’un buténolide. Cette voie fut couronnée de succès car la (-)-ent-plakortolide I et la seco-plakortolide E ont été synthétisée

Étude de la synthèse des plakortolides : synthèses asymétriques de la ent-plakortolide I et de la seco-plakortolide E

In this thesis manuscript are described our synthetic efforts and the first total synthesis of two natural products isolated from the sponges of the genus Plakortis. In total, two different synthetic approaches were studied to finally accomplish the synthesis of plakortolide I. The first approach is an extension of the method developed by our group which consists in the creation of the 1,2-dioxane cycle by intramolecular opening of vinyl epoxide with β-hydroperoxy group. Firstly, we was interested in the preparation of alkoxymethylhexa-2,5-dien-1-ol. We have also tried to create the 1,2-dioxane cycle by double opening of bis-1,5-epoxide with hydrogen peroxide. Further more we have synthesised trisubstituted β-hydroperoxy vinyl epoxide, precursor of 1,2-dioxan ring, from R-epichlorohydrin. During this synthesis a procedure of chemoselective methylenation of ketone in the presence of epoxide by Nysted reagent and Ti(OiPr)2Cl2 was developed. Finally, (-)-ent-plakortolide I and seco-plakortolide E were synthesised by intramolecular Michael addition of hydroperoxide to double bond of the butenolide moietyDans ce mémoire de thèse sont décrits nos efforts synthétiques qui ont conduits à la première synthèse totale de deux produits naturels isolés d’éponges marines du genre Plakortis. Deux approches synthétiques des plakortolides ont été successivement étudiées pour finalement aboutir à la synthèse de la plakortolide I qui comporte un cycle endoperoxide à 6 chainons (1,2-dioxane). La première approche qui est une extension d’une méthode développée au laboratoire consistait à créer le cycle 1,2-dioxane par une ouverture intramoléculaire d’un époxyde vinylique par un groupement hydroperoxyde en β de l’époxyde. Dans un premier temps, nous nous sommes intéressés à la préparation d’un intermédiaire de synthèse, un alkoxyméthylhexa-2,5-dien-1-ol. Nous avons aussi tenté de créer le cycle 1,2-dioxane par une double ouverture d’un di époxyde 1,5 par de l’eau oxygénée. Nous avons ensuite modifié notre stratégie de synthèse en introduisant au début de la synthèse la chaine latérale de la plakortolide I en partant de la R-épichlorhydrine commerciale. Nous avons ainsi synthétisé le β-hydroperoxy vinyl époxyde trisubstitué, précurseur du cycle 1,2-dioxane. Lors de cette synthèse, nous avons mis au point une méthode efficace et chimiosélective de méthylenation d’une cétone en présence d’un ester utilisant le réactif de Nysted catalysé par Ti(OiPr)2Cl2. La seconde approche du système bicyclique peroxylactone fait appel à une addition de Michael intramoléculaire d’un hydroperoxyde sur la double liaison d’un buténolide. Cette voie fut couronnée de succès car la (-)-ent-plakortolide I et la seco-plakortolide E ont été synthétisée

Total Synthesis of <i>seco</i>-Plakortolide E and (−)-<i>ent</i>-Plakortolide I: Absolute Configurational Revision of Natural Plakortolide I

A first total synthesis of (−)-<i>ent</i>-plakortolide I and <i>seco</i>-plakortolide E was accomplished from (<i>S</i>)-2-methylglycidol. The relevant key reactions involve a diastereoselective Mukaiyama aldol reaction, a regioselective hydroperoxysilylation, and elaboration of the 1,2-dioxane ring by intramolecular Michael addition of a hydroperoxide group to a butenolide. This synthesis allowed the revision of the absolute configuration of plakortolide I and structural revision of plakortolide E

Identification of the Functional Binding Site for the Convulsant Tetramethylenedisulfotetramine in the Pore of the α 2 β 3 γ 2 GABAA Receptor.

Tetramethylenedisulfotetramine (TETS) is a so-called "caged" convulsant that is responsible for thousands of accidental and malicious poisonings. Similar to the widely used GABA receptor type A (GABAA) antagonist picrotoxinin, TETS has been proposed to bind to the noncompetitive antagonist (NCA) site in the pore of the receptor channel. However, the TETS binding site has never been experimentally mapped, and we here set out to gain atomistic level insights into how TETS inhibits the human α 2 β 3 γ 2 GABAA receptor. Using the Rosetta molecular modeling suite, we generated three homology models of the α 2 β 3 γ 2 receptor in the open, desensitized, and closed/resting state. Three different ligand-docking algorithms (RosettaLigand, Glide, and Swissdock) identified two possible TETS binding sites in the channel pore. Using a combination of site-directed mutagenesis, electrophysiology, and modeling to probe both sites, we demonstrate that TETS binds at the T6' ring in the closed/resting-state model, in which it shows perfect space complementarity and forms hydrogen bonds or makes hydrophobic interactions with all five pore-lining threonine residues of the pentameric receptor. Mutating T6' in either the α 2 or β 3 subunit reduces the IC50 of TETS by ∼700-fold in whole-cell patch-clamp experiments. TETS is thus interacting at the NCA site in the pore of the GABAA receptor at a location that is overlapping but not identical to the picrotoxinin binding site. SIGNIFICANCE STATEMENT: Our study identifies the binding site of the highly toxic convulsant tetramethylenedisulfotetramine (TETS), which is classified as a threat agent by the World Health Organization. Using a combination of homology protein modeling, ligand docking, site-directed mutagenesis, and electrophysiology, we show that TETS is binding in the pore of the α2β3γ2 GABA receptor type A receptor at the so-called T6' ring, wherein five threonine residues line the permeation pathway of the pentameric receptor channel

The epoxy fatty acid pathway enhances cAMP in mammalian cells through multiple mechanisms.

The cellular mechanism by which epoxy fatty acids (EpFA) improves disease status is not well characterized. Previous studies suggest the involvement of cellular receptors and cyclic AMP (cAMP). Herein, the action of EpFAs derived from linoleic acid (LA), arachidonic acid (ARA), and docosahexaenoic acid on cAMP levels was studied in multiple cell types to elucidate relationships between EpFAs, receptors and cells origin. cAMP levels were enhanced in HEK293 and LLC-PK1 cells by EpFAs from LA and ARA. Using selective antagonists, the EpFA effects on cAMP levels appear dependent on the prostaglandin E2 receptor 2 (EP2) but not 4 (EP4). Human coronary artery smooth muscle cells responded similarly to the EpFAs. However, we were not able to show the involvement of any of the receptors tested in this cell type. The results pinpointed distinct cell lines and receptor subtypes that natively respond to EpFA

Identification of the Functional Binding Site for the Convulsant Tetramethylenedisulfotetramine in the Pore of the α 2 β 3 γ 2 GABAA Receptor.

Tetramethylenedisulfotetramine (TETS) is a so-called "caged" convulsant that is responsible for thousands of accidental and malicious poisonings. Similar to the widely used GABA receptor type A (GABAA) antagonist picrotoxinin, TETS has been proposed to bind to the noncompetitive antagonist (NCA) site in the pore of the receptor channel. However, the TETS binding site has never been experimentally mapped, and we here set out to gain atomistic level insights into how TETS inhibits the human α 2 β 3 γ 2 GABAA receptor. Using the Rosetta molecular modeling suite, we generated three homology models of the α 2 β 3 γ 2 receptor in the open, desensitized, and closed/resting state. Three different ligand-docking algorithms (RosettaLigand, Glide, and Swissdock) identified two possible TETS binding sites in the channel pore. Using a combination of site-directed mutagenesis, electrophysiology, and modeling to probe both sites, we demonstrate that TETS binds at the T6' ring in the closed/resting-state model, in which it shows perfect space complementarity and forms hydrogen bonds or makes hydrophobic interactions with all five pore-lining threonine residues of the pentameric receptor. Mutating T6' in either the α 2 or β 3 subunit reduces the IC50 of TETS by ∼700-fold in whole-cell patch-clamp experiments. TETS is thus interacting at the NCA site in the pore of the GABAA receptor at a location that is overlapping but not identical to the picrotoxinin binding site. SIGNIFICANCE STATEMENT: Our study identifies the binding site of the highly toxic convulsant tetramethylenedisulfotetramine (TETS), which is classified as a threat agent by the World Health Organization. Using a combination of homology protein modeling, ligand docking, site-directed mutagenesis, and electrophysiology, we show that TETS is binding in the pore of the α2β3γ2 GABA receptor type A receptor at the so-called T6' ring, wherein five threonine residues line the permeation pathway of the pentameric receptor channel

Design and Synthesis of Core–Shell Carbon Polymer Dots with Highly Stable Fluorescence in Polymeric Materials

In recent years, fluorescent carbon dots have attracted great attention due to their good luminescence and low toxicity. Here, blue fluorescent core-shell structured carbon polymer dots (CPDs) with high stability under a wide range of pH values, long storage time and excellent fluorescence in various solvents and even in solid state were prepared by hydrothermal synthesis of dendritic tris(2-aminoethyl)amine (TAEA) and citric acid. The CPDs core structure provides strong fluorescent luminescence, a shell structure of the core possesses high amount of dendritic primary amino groups connected by ethylene groups to the core. This unique structure prevents aggregation of the cores and self-quenching effect of CPDs. As a result, the CPDs have high fluorescence in both aqueous and hydrophobic solutions and even as pure solid-state powder. In addition, the CPDs are also insensitive to pH of solutions, and the fluorescence intensity of the solution was stable in the pH range of 4-14. The CPDs embedded polymer films and fibers revealed excellent fluorescent properties